Key Drivers
- Gross margin strength
- Negative equity burden
- Cash burn persists
AIAI Summary
PHAT has shifted from a speculative biotech to a commercial execution story, with VOQUEZNA driving 1.1M+ prescriptions and 217% FY2025 revenue growth, but the stock now hinges on sustaining launch momentum and expense discipline long enough to reach the Q3 2026 profitability target while avoiding balance-sheet strain.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross margin strength
- •Negative equity burden
- •Cash burn persists
PHAT has strong gross margins and decent liquidity, but persistent operating losses, negative cash flow, and deeply negative equity make the balance sheet highly risky.
Price Behavior
Key Price Behavior Insights:
- •Support Rebound
- •Resistance Cap
- •Momentum Fade
Over the last month, PHAT bounced from the $11.20-$11.30 support zone but repeatedly stalled near $13.00-$13.50, and the latest pullback below $12.00-$12.20 keeps the short-term setup cautious.
Sharp pullback on 2026-05-15 after prior strength weakened the breakout attempt
Sentiment & News
Key News Insights:
- •Loss Narrowing
- •Revenue Beat
- •DDW Spotlight
Phathom Pharmaceuticals narrowed its Q1 loss, beat revenue expectations, and is using upcoming DDW 2026 messaging to reinforce focus on VOQUEZNA and its GI growth story.
The earnings beat and continued product promotion could support near-term sentiment, though sustained upside will depend on execution and commercial momentum
Similar Companies in Healthcare
Other companies in the same sector with AI ratings